Hikma Pharmaceuticals has acquired six products from Boehringer Ingelheim GmbH (Boehringer Ingelheim).
Boehringer Ingelheim is a related party of Hikma for the purposes of the UKLA Listing Rules (LRs) by its 17% shareholding in Hikma.
Hikma has acquired five products in Germany, Alupent, Gastrozepin, Paracefan, Partusisten and Spiropent and one product, Mantadan, in Italy, together with inventory at closing and the supply by Boehringer Ingelheim of a stockpile of the products to cover a transition period of 20 months, for an aggregate consideration of €3 million.